Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Q1 FY26 earnings call: Revenue & Margins
Q1 FY26 earnings call: what management said on revenue, margins and capex.
The short version
India business expected to sustain double-digit growth, leveraging innovative product launches beyond branded generics, targeting to be ranked number 5 in the market organically and through licensing (Page 16). Profit after tax for Q1FY26 was ₹1,419 crores ($166 million), a 2% YoY growth but 11% QoQ decline, at 16.6% of revenues.
From Dr Reddys Laboratories Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- India business expected to sustain double-digit growth, leveraging innovative product launches beyond branded generics, targeting to be ranked number 5 in the market organically and through licensing (Page 16).
- PSAI business aims for about $100 million sales in the full fiscal year, returning to a double-digit growth trajectory (Page 14).
- North America base business expected flat to single-digit growth, dependent on successful product launches (Page 8).
- Semaglutide and GLP-1 product portfolio (26 products) seen as a major growth driver over a decade, starting significant revenue from FY26 (Pages 15 and 12).
2 more points from Dr Reddys Laboratories Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
Read what Dr Reddys Laboratories Ltd said on margins in the Q1 FY26 call
Free account with your mobile number. We text a one-time code, no password.
Capital Expenditure Plans
- Capex for FY26 is expected to be ₹2,500 to ₹2,700 crores, comparable to last year's levels.
- Major investments are directed toward peptides and biosimilars.
- Strategic investments include business development (BD) opportunities, with financial capacity of $2-2.5 billion available for BD.
- Focus on four growth levers: baseline growth, special products, cost optimization, and BD.
- Actively engaging in BD activities to pursue acquisitions and licensing deals.
- Biosimilar portfolio expansion through in-licensing and deals, targeting key US biosimilars like abatacept, denosumab, pembrolizumab, and daratumumab.
2 more points from Dr Reddys Laboratories Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Dr Reddys Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.
Dr Reddys Laboratories Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹7.5K Cr, net profit ₹221 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Dr Reddys Laboratories Ltd's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q4 FY25 earnings call →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- RPG LifeScience. (Q1 FY26)
168.9 crores vs Rs. Key concall takeaways from RPG Life Sciences Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- SMS Pharma. (Q1 FY26)
Q1FY26 revenue from operations: ₹196.05 crore . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector…
- Influx Health. (Q1 FY26)
FY25 revenue from operations: ₹104.9 crores, up 5% YoY from ₹99.9 crores in FY24 (Page 28 & 26). Key concall takeaways from Influx Healthtech Ltd's Q1 FY26…
- Shree Ganesh Rem (Q1 FY26)
Q1FY26 Revenue from Operations: ₹24.67 crores . Key concall takeaways from Shree Ganesh Remedies Ltd's Q1 FY26 earnings call — and how it ranks against sector…
Arthneeti Pro · Annual
Dr Reddys Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Dr Reddys Laboratories Ltd Q1 FY26 results?
India business expected to sustain double-digit growth, leveraging innovative product launches beyond branded generics, targeting to be ranked number 5 in the market organically and through licensing (Page 16). Profit after tax for Q1FY26 was ₹1,419 crores ($166 million), a 2% YoY growth but 11% QoQ decline, at 16.6% of revenues.
What is Dr Reddys Laboratories Ltd share price analysis?
Dr Reddys Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 31.1 with a market cap of ₹100,161 Cr. Investors should review the full earnings analysis for detailed insights.
Is Dr Reddys Laboratories Ltd planning capital expenditure?
Capex for FY26 is expected to be ₹2,500 to ₹2,700 crores, comparable to last year's levels.
Keep Dr Reddys Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.